COVID-19 vaccines are not as effective in immunocompromised individuals as they are in the general population, due to an inability to produce a robust protective response to the vaccine.
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.
